Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable
As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.
Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.
Featuring key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this is your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.
In the rapidly advancing field of TPD research, this summit is an excellent opportunity to see a number of amazing cutting-edge approaches from academia, biotech and pharma.
Kazuteru Aoki, Vice President of Biology, FIMECS, Inc.
In a rapidly evolving drug development landscape, engaging with global experts at the TPD Summit is not just an opportunity—it’s a strategic imperative to validate and sharpen the competitive edge of our protein degrader platform.
Hyunson Jo, Founder and CEO, Pin Therapeutics
The TPD&IP Summit is THE meeting each year to learn from the best and brightest minds working on PROTACs, DACs, and molecular glues -- it is THE not-miss meeting to stay on top of this rapidly evolving field.
Brent Meadows, CBO, Polymed Bio
Explore the Full Event Guide
- 80+ World Class Speakers
- 4 Days of Exclusive Data-Driven TPD Content
- CXO and VC Panel Discussions
- Bespoke Networking & Partnering Opportunities
- The World’s Leading Event for the TPD & Induced Proximity Industry
Hear From TPD Co-Founders
With Arvinas’s recent NDA submission marking the potential first-ever approved PROTAC, and exciting clinical progress from leaders like Kymera Therapeutics, Nurix Therapeutics, and others, there couldn’t be a more fitting moment to hear from Ray and Craig in what promises to be a landmark year for TPD.
Official Partners
Program Partners
Expertise Partner
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights on the TPD innovations during our packed agenda, interactive roundtables, and new CCOs & VC panel discussions.
Partner With Us
Position yourself alongside as the leading solution provider to ensure your brand is at the heart of TPD biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.